High-Tech Gründerfonds Management GmbH is a venture capital firm based in Bonn, Germany, specializing in early-stage investments in high-tech startups. Established in 2005, the firm focuses on technology-driven companies across various sectors, including information and communication technology, life sciences, healthcare, automation, and cleantech. HTGF typically invests in companies that have been operational for no more than one year, aiming to contribute up to €0.6 million in initial funding and up to €3 million in follow-on financing. The firm seeks a minority stake, generally around 15%, and provides a subordinated loan convertible into equity, with deferred interest for up to four years to support liquidity. With a total investment volume of approximately €895.5 million across three funds, HTGF has successfully supported over 500 startups and attracted more than €2 billion in follow-on investments from external sources. The firm's investors include notable public and private entities, underscoring its role as a key player in fostering innovation and growth within the German startup ecosystem.
Hema.to is a developer of clinical support software that specializes in automated, AI-powered detection suggestions for blood cancer, utilizing flow cytometry data. The company's platform offers comprehensive decision support, taking users from raw flow files to complete diagnostic reports. By focusing on the needs of hematology laboratories, Hema.to aims to enhance operational efficiency while ensuring high-quality results. Its tools are specifically designed to meet the unique requirements of clinical flow, empowering labs to provide better patient care through advanced technology.
Hema.to
Seed Round in 2023
Hema.to is a developer of clinical support software that specializes in automated, AI-powered detection suggestions for blood cancer, utilizing flow cytometry data. The company's platform offers comprehensive decision support, taking users from raw flow files to complete diagnostic reports. By focusing on the needs of hematology laboratories, Hema.to aims to enhance operational efficiency while ensuring high-quality results. Its tools are specifically designed to meet the unique requirements of clinical flow, empowering labs to provide better patient care through advanced technology.
Ebenbuild
Seed Round in 2022
Ebenbuild is a health tech company that utilizes advanced research from TU Munich to develop a platform focused on respiratory diseases. The company offers a deep tech solution that includes two initial applications aimed at enhancing drug development and patient care. One application focuses on digital trials, enabling biotech and pharmaceutical companies to optimize drug delivery to the lungs through predictive models, thereby reducing risks and accelerating clinical development. The second application integrates with hospital IT systems to provide precise, actionable intelligence at the patient bedside, particularly for individuals with Acute Respiratory Distress Syndrome (ARDS). This technology personalizes mechanical ventilation settings, improving both short-term and long-term patient outcomes. By continuously expanding its platform to address various medical indications, Ebenbuild aims to deliver significant benefits to patients, healthcare providers, and payors.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.